- Home
- ALLO
as 09-06-2024 4:00pm EST
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, primarily generated from collaborations and licensing agreements, supports their research and development efforts.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 545.8M | IPO Year: | 2018 |
| Target Price: | $10.26 | AVG Volume (30 days): | 1.6M |
| Analyst Decision: | Buy | Number of Analysts: | 12 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.61 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.01 - $5.78 | Next Earning Date: | 10-31-2024 |
| Revenue: | $65,000 | Revenue Growth: | 6.56% |
| Revenue Growth (this year): | -30.88% | Revenue Growth (next year): | 6292.80% |
Stock Insider Trading Activity of Allogene Therapeutics Inc. (ALLO)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| MESSEMER DEBORAH M. | ALLO | Director | Jun 18 '24 | Sell | $2.28 | 18,641 | $42,488.43 | 166,765 |
Latest Allogene Therapeutics Inc. News
ALLO Breaking Stock News: Dive into ALLO Ticker-Specific Updates for Smart Investing
Zacks
2 days ago
Allogene Therapeutics (ALLO) Up 6.4% Since Last Earnings Report: Can It Continue?
Simply Wall St.
a month ago
Allogene Therapeutics Second Quarter 2024 Earnings: US$0.35 loss per share (vs US$0.53 loss in 2Q 2023)
Zacks
a month ago
Allogene (ALLO) Posts Narrower Than Expected Loss in Q2
MT Newswires
a month ago
Truist Adjusts Allogene Therapeutics' PT to $14 From $17, Keeps Buy Rating
MT Newswires
a month ago
Oppenheimer Adjusts Allogene Therapeutics Price Target to $11 From $13, Maintains Outperform Rating
GlobeNewswire
a month ago
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
Associated Press Finance
a month ago
Allogene Therapeutics: Q2 Earnings Snapshot
GlobeNewswire
a month ago
Allogene Therapeutics Reports Second Quarter 2024 Financial Results and Business Update
Compare ALLO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ALLO Allogene Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.